The disclosure is in part directed to crystalline forms of ((S)-2-amino-3-(3,4-dihydroxyphenyl)propanoyl)-A-tyrosine and pharmaceutical compositions thereof.
A bi-functional magnetic mechanism generates a magnetic attraction force to magnetically engage a disposable and reusable parts of a pump device, and, at the same time, the bi-functional magnetic mechanism uses the same magnetic field to detect an engagement between the two parts of the pump device. The mechanism includes a permanent magnet to produce magnetic field(s) that zero out a net magnetic field at a sensor, an asymmetrical metal plate (AMP) to magnetically disrupt (deflect, redirect) the magnetic field(s) at the sensor, and a magnetic field sensor to sense the magnetic disruption. The magnet and the sensor are incorporated in the reusable part of the pump device such that the magnetic field sensor is circumferentially surrounded by the magnet. The AMP is incorporated in the disposable part such that the AMP subtends the sensor (i.e., adjacent to the sensor) when the disposable part and reusable part are engaged.
The present invention provides a method for treatment of a neurological or movement disorder, e.g., Parkinson's disease, in an individual in need thereof, by parenteral administration of a composition comprising carbidopa and levopoda, or pharmaceutically acceptable salts thereof, and concomitant oral administration of a catechol-O-methyl transferase (COMT) inhibitor, e.g., entacapone or tolcapone.
Disclosed is a method for the treatment of a neurological or movement disorder, e.g., Parkinson's disease, in an individual in need thereof, by parenteral administration of levodopa and a dopa decarboxylase inhibitor (DDCI), such as carbidopa, benserazide or any combination thereof, concomitantly with oral administration of levodopa, a DDCI, such as carbidopa, benserazide, or any combination thereof.
Provided herein, in part, is a method of treating a neurological or movement disorder in a patient in need thereof, comprising subcutaneously administering to said patient a pharmaceutically acceptable composition comprising levodopa and optionally carbidopa and optionally entacapone or tolcapone, or pharmaceutically acceptable salts thereof, wherein said composition is administered substantially continuously, and compositions that can be used in the disclosed methods.
A61K 31/122 - Cétones ayant l'atome d'oxygène lié directement à un cycle, p. ex. quinones, vitamine K1, anthraline
A61K 31/133 - Amines, p. ex. amantadine ayant des groupes hydroxyle, p. ex. sphingosine
A61K 31/195 - Acides carboxyliques, p. ex. acide valproïque ayant un groupe amino
A61K 31/197 - Acides carboxyliques, p. ex. acide valproïque ayant un groupe amino les groupes amino et carboxyle étant liés à la même chaîne carbone acyclique, p. ex. acide gamma-aminobutyrique [GABA], bêta-alanine, acide epsilon-aminocaproïque ou acide pantothénique
A61K 31/277 - NitrilesIsonitriles ayant un cycle, p. ex. vérapamil
A61K 47/18 - AminesAmidesUréesComposés d’ammonium quaternaireAcides aminésOligopeptides ayant jusqu’à cinq acides aminés
A61K 47/20 - Composés organiques, p. ex. hydrocarbures naturels ou synthétiques, polyoléfines, huile minérale, gelée de pétrole ou ozocérite contenant du soufre, p. ex. sulfoxyde de diméthyle [DMSO], docusate, laurylsulfate de sodium ou acides aminosulfoniques
A61K 47/22 - Composés hétérocycliques, p. ex. acide ascorbique, tocophérol ou pyrrolidones
A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
7.
METHODS AND COMPOSITIONS FOR TREATING PARKINSON’S DISEASE
Disclosed is a method for the treatment of a neurological or movement disorder, e.g., Parkinson's disease, in an individual in need thereof, by parenteral administration of levodopa, a levodopa salt, a levodopa prodrug and a dopa decarboxylase inhibitor (DDCI), such as carbidopa, a carbidopa salt, a carbidopa prodrug, benserazide or any combination thereof, concomitantly with oral administration of levodopa, a DDCI, such as carbidopa, benserazide, or any combination thereof.
Disclosed herein are formulations containing carbidopa and optionally levodopa, arginine, and other components that have reduced levels of impurities and toxins, particularly degradation productions. Also disclosed herein are methods of treatment diseases or conditions relating to a loss of dopamine or dopaminergic neurons using such formulations, methods of making such formulations, and kits that include such formulations.
A61K 47/20 - Composés organiques, p. ex. hydrocarbures naturels ou synthétiques, polyoléfines, huile minérale, gelée de pétrole ou ozocérite contenant du soufre, p. ex. sulfoxyde de diméthyle [DMSO], docusate, laurylsulfate de sodium ou acides aminosulfoniques
A61K 47/22 - Composés hétérocycliques, p. ex. acide ascorbique, tocophérol ou pyrrolidones
A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
9.
METHODS AND COMPOSITIONS FOR REDUCING SYMPTOMS OF PARKINSON'S DISEASE
Disclosed is a method for the treatment of a neurological or movement disorder, e.g., Parkinson's disease, in a patient in need thereof, by parenteral administration of levodopa and a dopa decarboxylase inhibitor (DDCI), such as carbidopa, benserazide or any combination thereof.
09 - Appareils et instruments scientifiques et électriques
Produits et services
Recorded software applications for smartphones, computers,
tablets, smart watches or other hand held communication
devices or downloadable software applications for
smartphones, computers, tablets, smart watches or other hand
held communication devices that collect, analyze and monitor
health, care, pharmaceutical and medical data that enables
the patient to receive data and control medical delivery
devices of pharmaceuticals, drugs, and fluids and further
enables remote communication of care providers with patients
and detect and monitor conditions and indications relating
to a person's health, medical treatment, medical compliance,
care, performance and control of medical delivery devices of
pharmaceuticals, drugs and fluids for the treatment of
Parkinson's disease (term considered too vague by the
International Bureau pursuant to Rule 13 (2) (b) of the
Regulations).
12.
METHODS AND COMPOSITIONS FOR REDUCING SYMPTOMS OF PARKINSON'S DISEASE
Disclosed is a method for the treatment of a neurological or movement disorder, e.g., Parkinson's disease, in a patient in need thereof, by parenteral administration of levodopa and a dopa decarboxylase inhibitor (DDCI), such as carbidopa, benserazide or any combination thereof.
Disclosed is a method for the treatment of a neurological or movement disorder, e.g., Parkinson's disease, in a patient in need thereof, by parenteral administration of levodopa and a dopa decarboxylase inhibitor (DDCI), such as carbidopa, benserazide or any combination thereof.
Disclosed is a method for the treatment of a neurological or movement disorder. e.g., Parkinson's disease, in an individual in need thereof, by parenteral administration of levodopa, a levodopa salt, a levodopa prodrug, or any combination thereof, and a dopa decarboxylase inhibitor (DDCI), such as carbidopa, a carbidopa salt, a carbidopa prodrug, benserazide or any combination thereof, concomitantly with oral administration of levodopa, a DDCI, such as carbidopa, benserazide, or any combination thereof.
09 - Appareils et instruments scientifiques et électriques
Produits et services
(1) Recorded software applications for smartphones, computers, tablets, smart watches or other hand held communication devices or downloadable software applications for smartphones, computers, tablets, smart watches or other hand held communication devices that collect, analyze and monitor health, care, pharmaceutical and medical data that enables the patient to receive data and control medical delivery devices of pharmaceuticals, drugs, and fluids and further enables remote communication of care providers with patients and detect and monitor conditions and indications relating to a person's health, medical treatment, medical compliance, care, performance and control of medical delivery devices of pharmaceuticals, drugs and fluids for the treatment of Parkinson's disease (term considered too vague by the International Bureau pursuant to Rule 13 (2) (b) of the Regulations).
09 - Appareils et instruments scientifiques et électriques
Produits et services
Recorded software applications for smartphones, computers, tablets, smart watches and hand held communication devices for use in allowing the user to collect,, analyze and monitor health, care, pharmaceutical and medical data that enables the patient to receive data and control medical delivery devices of pharmaceuticals, drugs, and fluids and further enables remote communication of care providers with patients and detect and monitor conditions and indications relating to a person's health, medical treatment, medical compliance, care, performance and control of medical delivery devices of pharmaceuticals, drugs and fluids for the treatment of Parkinson's disease; downloadable software applications for smartphones, computers, tablets, smart watches and hand held communication devices for use in allowing the user to collect, analyze and monitor health care, pharmaceutical and medical data that enables the patient to receive data and control medical delivery devices of pharmaceuticals, drugs, and fluids and further enables remote communication of care providers with patients and detect and monitor conditions and indications relating to a person's health, medical treatment, medical compliance, health care, performance and control of medical delivery devices of pharmaceuticals, drugs and fluids for the treatment of Parkinson's disease
19.
STABILIZED LIQUID COMPOSITIONS COMPRISING A LEVODOPA-TYROSINE CONJUGATE AND USES THEREOF
Disclosed herein are levodopa prodrug compounds and methods for their use. Further disclosed herein are liquid pharmaceutical formulations comprising a levodopa-tyrosine conjugate and a stabilizer, wherein the liquid pharmaceutical formulations may further comprise a decarboxylase inhibitor, such as carbidopa, an antioxidant, a solvent, or any other pharmaceutically acceptable excipient. Further disclosed are methods of treating generative conditions and/or conditions characterized by reduced levels of dopamine in the brain, such as Parkinson's disease, comprising administering the disclosed prodrugs and/or liquid pharmaceutical formulations.
A61K 47/54 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique
A61K 31/198 - Alpha-amino-acides, p. ex. alanine ou acide édétique [EDTA]
A61K 47/10 - AlcoolsPhénolsLeurs sels, p. ex. glycérolPolyéthylène glycols [PEG]PoloxamèresAlkyléthers de PEG/POE
A61K 47/18 - AminesAmidesUréesComposés d’ammonium quaternaireAcides aminésOligopeptides ayant jusqu’à cinq acides aminés
A61K 47/20 - Composés organiques, p. ex. hydrocarbures naturels ou synthétiques, polyoléfines, huile minérale, gelée de pétrole ou ozocérite contenant du soufre, p. ex. sulfoxyde de diméthyle [DMSO], docusate, laurylsulfate de sodium ou acides aminosulfoniques
A61K 47/22 - Composés hétérocycliques, p. ex. acide ascorbique, tocophérol ou pyrrolidones
A mechanism for a pump device includes a rotatable earn body that is axially affixed to a distal end of a plunger rod stowable In a pump device and rotatable around the plunger rod. The earn body includes cam surfaces to cammingly co-act with stationary cam pins in the plunger head. Co-action between the cam surfaces of the cam body and the cam pins causes the cam body to rotate in the plunger head to, and from, an engagement angular position in which the cam body and the plunger head are engaged, to a. disengagement, angular position in winch the cam body and the plunger head are disengaged, via an alternating series of push-pull angular positions configured for alternately pushing and pulling the plunger head in the syringe. Rotating the cam body from one angular position to another is implemented by means of reciprocating axial movement of the plunger rod.
(1) Medical devices, namely, infusion pumps for the subcutaneous delivery of drugs for Parkinson's disease, for use subject to physician's prescription
26.
PLUNGER ROD RELEASABLY ATTACHABLE TO PLUNGER HEAD IN A PUMP DEVICE
A61M 5/14 - Dispositifs de perfusion, p. ex. perfusion par gravitéPerfusion sanguineAccessoires à cet effet
A61M 5/142 - Perfusion sous pression, p. ex. utilisant des pompes
A61M 5/145 - Perfusion sous pression, p. ex. utilisant des pompes utilisant des réservoirs sous pression, p. ex. au moyen de pistons
A61M 5/168 - Moyens pour commander l'écoulement des agents vers le corps ou pour doser les agents à introduire dans le corps, p. ex. compteurs de goutte-à-goutte
27.
Continuous Administration of Dopa Decarboxylase Inhibitors and Compositions for Same
Disclosed herein are compositions that include for example the arginine salt of carbidopa, and methods for treating neurological or movement diseases or disorders such as restless leg syndrome, Parkinson's disease, secondary parkinsonism, Huntington's disease, Parkinson's like syndrome, PSP, MSA, ALS, Shy-Drager syndrome and conditions resulting from brain injury including carbon monoxide or manganese intoxication, using substantially continuous administration of carbidopa or salt thereof together with administration of levodopa.
C07C 243/18 - Hydrazines ayant des atomes d'azote de groupes hydrazine liés à des atomes de carbone acycliques d'un squelette carboné non saturé contenant des cycles
C07C 279/14 - Dérivés de la guanidine, c.-à-d. composés contenant le groupe les atomes d'azote liés par des liaisons simples ne faisant pas partie de groupes nitro ou nitroso ayant des atomes d'azote de groupes guanidine liés à des atomes de carbone acycliques d'un squelette carboné étant substitué de plus par des groupes carboxyle
The disclosure is in part directed to crystalline forms of ((S)-2-amino-3-(3,4- dihydroxyphenyl)propanoyl)-A-tyrosine and pharmaceutical compositions thereof.
A bi-functional magnetic mechanism generates a magnetic attraction force to magnetically engage a disposable and reusable parts of a pump device, and, at the same time, the bi- functional magnetic mechanism uses the same magnetic field to detect an engagement between the two parts of the pump device. The mechanism includes a permanent magnet to produce magnetic field(s) that zero out a net magnetic field at a sensor, an asymmetrical metal plate (AMP) to magnetically disrupt (deflect, redirect) the magnetic field(s) at the sensor, and a magnetic field sensor to sense the magnetic disruption. The magnet and the sensor are incorporated in the reusable part of the pump device such that the magnetic field sensor is circumferentially surrounded by the magnet. The AMP is incorporated in the disposable part such that the AMP subtends the sensor (i.e., adjacent to the sensor) when the disposable part and reusable part are engaged.
Medical devices, namely, infusion pumps for the subcutaneous delivery of drugs for the treatment of Parkinson's disease, for use subject to physician's prescription
Disclosed herein are formulations containing carbidopa and optionally levodopa, arginine, and other components that have reduced levels of impurities and toxins, particularly degradation productions. Also disclosed herein are methods of treatment diseases or conditions relating to a loss of dopamine or dopaminergic neurons using such formulations, methods of making such formulations, and kits that include such formulations.
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 31/133 - Amines, p. ex. amantadine ayant des groupes hydroxyle, p. ex. sphingosine
A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
A61K 47/18 - AminesAmidesUréesComposés d’ammonium quaternaireAcides aminésOligopeptides ayant jusqu’à cinq acides aminés
A61K 47/22 - Composés hétérocycliques, p. ex. acide ascorbique, tocophérol ou pyrrolidones
A61K 31/198 - Alpha-amino-acides, p. ex. alanine ou acide édétique [EDTA]
A61K 47/20 - Composés organiques, p. ex. hydrocarbures naturels ou synthétiques, polyoléfines, huile minérale, gelée de pétrole ou ozocérite contenant du soufre, p. ex. sulfoxyde de diméthyle [DMSO], docusate, laurylsulfate de sodium ou acides aminosulfoniques
32.
METHODS AND COMPOSITIONS FOR TREATING PARKINSON'S DISEASE
Disclosed is a method for the treatment of a neurological or movement disorder, e.g., Parkinson's disease, in an individual in need thereof, by parenteral administration of levodopa, a levodopa salt, a levodopa prodrug and a dopa decarboxylase inhibitor (DDCI), such as carbidopa, a carbidopa salt, a carbidopa prodrug, benserazide or any combination thereof, concomitantly with oral administration of levodopa, a DDCI, such as carbidopa, benserazide, or any combination thereof.
An improved device delivers a fluid medicament to the subcutaneous tissue of a user. The device is better suited for patients with Parkinson's Disease and other central nervous system disorders, than conventional infusion devices. The device can include a reusable part including a drive component (e.g., motor) and control electronics and a disposable part including a medicament reservoir. Medicament can be evacuated from the medicament reservoir by a plunger assembly that includes a plunger attached to a lead screw that is rotated by a nut, all within the disposable part. The device can be fluidically coupled with the tissue via a flexible cannula. Various embodiments relate to an improved cannula insertion mechanism that delivers the cannula under a force applied by a spring. Various embodiments relate to improved filling of the device, for example, using a vial adapter and an automated filling station.
H03H 9/54 - Filtres comprenant des résonateurs en matériau piézo-électrique ou électrostrictif
A61M 5/145 - Perfusion sous pression, p. ex. utilisant des pompes utilisant des réservoirs sous pression, p. ex. au moyen de pistons
A61M 5/172 - Moyens pour commander l'écoulement des agents vers le corps ou pour doser les agents à introduire dans le corps, p. ex. compteurs de goutte-à-goutte électriques ou électroniques
A61M 5/14 - Dispositifs de perfusion, p. ex. perfusion par gravitéPerfusion sanguineAccessoires à cet effet
A61M 5/315 - PistonsTiges de pistonGuidage, blocage, ou limitation des mouvements de la tigeAccessoires disposés sur la tige pour faciliter le dosage
A61M 5/34 - Structures pour le raccordement de l'aiguille
H03H 9/64 - Filtres utilisant des ondes acoustiques de surface
Systems and methods are provided for evaluating a Parkinson disease (PD) condition or a progression thereof by using voice analysis, and for treating the PD condition. Evaluation of the PD condition or of the progression thereof may be performed instantly or over time by analyzing current voice samples of the PD subject and, optionally, historical voice samples that are stored in a data storage unit, determining pertinent voice characteristics of the PD subject based on the analysis of the voice samples, and evaluating the PD condition, or the progression thereof by comparing current voice characteristics to similar voice characteristics. Treating a PD condition may include, for example, adjusting a drug delivery parameter to a level that is treatment-wise beneficial, for example, in preventing or delaying the onset of “off” periods or shortening the duration of an “off” period, or ameliorating a Hypokinetic dysarthria (HD) symptom or another PD symptom.
Disclosed is a method for the treatment of a neurological or movement disorder, e.g., Parkinson's disease, in an individual in need thereof, by parenteral administration of levodopa, a levodopa salt, a levodopa prodrug, or any combination thereof, and a dopa decarboxylase inhibitor (DDCI), such as carbidopa, a carbidopa salt, a carbidopa prodrug, benserazide or any combination thereof, concomitantly with oral administration of levodopa, a DDCI, such as carbidopa, benserazide, or any combination thereof.
An improved device delivers a fluid medicament to the subcutaneous tissue of a user. The device is better suited for patients with Parkinson's Disease and other central nervous system disorders, than conventional infusion devices. The device can include a reusable part including a drive component (e.g., motor) and control electronics and a disposable part including a medicament reservoir. Medicament can be evacuated from the medicament reservoir by a plunger assembly that includes a plunger attached to a lead screw that is rotated by a nut, all within the disposable part. The device can be fluidically coupled with the tissue via a flexible cannula. Various embodiments relate to an improved cannula insertion mechanism that delivers the cannula under a force applied by a spring. Various embodiments relate to improved filling of the device, for example, using a vial adapter and an automated filling station.
A61M 5/142 - Perfusion sous pression, p. ex. utilisant des pompes
A61M 5/145 - Perfusion sous pression, p. ex. utilisant des pompes utilisant des réservoirs sous pression, p. ex. au moyen de pistons
A61M 5/315 - PistonsTiges de pistonGuidage, blocage, ou limitation des mouvements de la tigeAccessoires disposés sur la tige pour faciliter le dosage
A61M 5/172 - Moyens pour commander l'écoulement des agents vers le corps ou pour doser les agents à introduire dans le corps, p. ex. compteurs de goutte-à-goutte électriques ou électroniques
Disclosed is a method for the treatment of a neurological or movement disorder, e.g., Parkinson’s disease, in an individual in need thereof, by parenteral administration of levodopa and a dopa decarboxylase inhibitor (DDCI), such as carbidopa, benserazide or any combination thereof, concomitantly with oral administration of levodopa, a DDCI, such as carbidopa, benserazide, or any combination thereof.
Disclosed herein are liquid pharmaceutical formulations comprising levodopa amino acid conjugates that may further comprise a decarboxylase inhibitor, such as carbidopa, an antioxidant, a solvent, or any other pharmaceutically acceptable excipient. Further disclosed are methods of treating generative conditions and/or conditions characterized by reduced levels of dopamine in the brain, such as Parkinson's disease, comprising administering the disclosed liquid pharmaceutical formulations. Disclosed also are LDAA conjugate compounds.
A61K 47/54 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique
A61K 31/198 - Alpha-amino-acides, p. ex. alanine ou acide édétique [EDTA]
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
42.
SYSTEMS AND METHODS FOR TREATING NEUROLOGICAL CONDITIONS IN PARKINSON DISEASE SUBJECTS
Systems and methods are provided for treating a condition associated with a Parkinson's disease (PD) subject, for example for treating or ameliorating motor and/or nonmotor symptoms or disorders in Parkinson's disease patients. An example system may include a sleep sensing circuitry and a drug dispensing device. The sleep sensing circuitry may be used to detect a sleep pattern of a PD patient, and the drug dispensing device may be used to continuously deliver a therapeutically effective compound to the PD patient based on the sleep pattern. Operational parameters of the drug delivery device (e.g., drug delivery flow rate and drug delivery timing) may be pre-programmed prior to bedtime and/or be adjusted in real time, for example during sleep, based on the detected sleep pattern to treat a condition associated with the PD subject, for example to optimize sleep, improve sleep quality, ameliorate non-motor disorders in the treated PD patient, etc.
A61M 5/172 - Moyens pour commander l'écoulement des agents vers le corps ou pour doser les agents à introduire dans le corps, p. ex. compteurs de goutte-à-goutte électriques ou électroniques
A61K 31/197 - Acides carboxyliques, p. ex. acide valproïque ayant un groupe amino les groupes amino et carboxyle étant liés à la même chaîne carbone acyclique, p. ex. acide gamma-aminobutyrique [GABA], bêta-alanine, acide epsilon-aminocaproïque ou acide pantothénique
A61K 31/198 - Alpha-amino-acides, p. ex. alanine ou acide édétique [EDTA]
A61K 31/277 - NitrilesIsonitriles ayant un cycle, p. ex. vérapamil
A61K 47/54 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique
43.
STABILIZED LIQUID COMPOSITIONS COMPRISING A LEVODOPA-TYROSINE CONJUGATE AND USES THEREOF
Disclosed herein are levodopa prodrug compounds and methods for their use. Further disclosed herein are liquid pharmaceutical formulations comprising a levodopa-tyrosine conjugate and a stabilizer, wherein the liquid pharmaceutical formulations may further comprise a decarboxylase inhibitor, such as carbidopa, an antioxidant, a solvent, or any other pharmaceutically acceptable excipient. Further disclosed are methods of treating generative conditions and/or conditions characterized by reduced levels of dopamine in the brain, such as Parkinson's disease, comprising administering the disclosed prodrugs and/or liquid pharmaceutical formulations.
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
Disclosed is a method for the treatment of a neurological or movement disorder, e.g., Parkinson's disease, in an individual in need thereof, by parenteral administration of levodopa and a dopa decarboxylase inhibitor (DDCI), such as carbidopa, benserazide or any combination thereof, concomitantly with oral administration of levodopa, a DDCI, such as carbidopa, benserazide, or any combination thereof.
Disclosed is a method for the treatment of a neurological or movement disorder, e.g., Parkinson's disease, in an individual in need thereof, by parenteral administration of levodopa and a dopa decarboxylase inhibitor (DDCI), such as carbidopa, benserazide or any combination thereof, concomitantly with oral administration of levodopa, a DDCI, such as carbidopa, benserazide, or any combination thereof.
A61K 31/197 - Acides carboxyliques, p. ex. acide valproïque ayant un groupe amino les groupes amino et carboxyle étant liés à la même chaîne carbone acyclique, p. ex. acide gamma-aminobutyrique [GABA], bêta-alanine, acide epsilon-aminocaproïque ou acide pantothénique
A61K 31/195 - Acides carboxyliques, p. ex. acide valproïque ayant un groupe amino
A61K 31/198 - Alpha-amino-acides, p. ex. alanine ou acide édétique [EDTA]
A61K 31/375 - Acide ascorbique, c.-à-d. vitamine CSes sels
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
Disclosed is a method for the treatment of a neurological or movement disorder, e.g., Parkinson's disease, in an individual in need thereof, by parenteral administration of levodopa and a dopa decarboxylase inhibitor (DDCI), such as carbidopa, benserazide or any combination thereof, concomitantly with oral administration of levodopa, a DDCI, such as carbidopa, benserazide, or any combination thereof.
Disclosed is a method for the treatment of a neurological or movement disorder, e.g., Parkinson's disease, in an individual in need thereof, by parenteral administration of levodopa and a dopa decarboxylase inhibitor (DDCI), such as carbidopa, benserazide or any combination thereof, concomitantly with oral administration of levodopa, a DDCI, such as carbidopa, benserazide, or any combination thereof.
Disclosed herein are liquid pharmaceutical formulations comprising levodopa amino acid conjugates that may further comprise a decarboxylase inhibitor, such as carbidopa, an antioxidant, a solvent, or any other pharmaceutically acceptable excipient. Further disclosed are methods of treating generative conditions and/or conditions characterized by reduced levels of dopamine in the brain, such as Parkinson's disease, comprising administering the disclosed liquid pharmaceutical formulations. Disclosed also are LDAA conjugate compounds.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
10 - Appareils et instruments médicaux
Produits et services
Pharmaceuticals, namely, pharmaceutical preparations for use
in preventing or treating conditions, diseases, or disorders
of the central nervous, neurological, cardiovascular,
endocrine, gastric or gastroenteric, hematologic,
immunologic, inflammatory, osteologic, or respiratory
systems; pharmaceutical preparations for use in prevention
or treatment of allergies or allergic responses, metabolic
disorders, psychiatric or emotional disorders, infection or
infectious diseases, pain; dermatologic pharmaceuticals for
treatment of comorbidities and side effect conditions caused
by a treatment of such conditions and/or stemming from the
reference diseases; delivery kits comprising dressings for
medical, surgical, and veterinary use; drug delivery agents,
namely, patches sold with medication. Medical devices for delivery of medicated and pharmaceutical
preparations; drug delivery device; infusion sets;
electromagnetic drug delivery apparatus for medical use;
medical apparatus, namely, implantable ports; medical
apparatus, namely, infusion and injection devices for
administering drugs; medical apparatus and medical
instruments for administering fluid, drugs, arid nutrition,
namely, infusion pumps, patch pumps, wearable injectors, and
handheld injectors; medical syringes; medical devices in the
nature of infusion pumps for drugs infusion and for
monitoring the infusion of drugs for use with integrated
software for transmission and/or receiving of drug infusion
data, data related to the infusion pumps, drug infusion
monitoring, filling or emptying of drug vials, and patient's
behavior and/or reaction to drugs, sold as a unit therewith;
drug delivery device for carrying pharmaceuticals or drugs
for medical treatment; drug delivery devices and accessories
thereof, namely, catheters, pen needles, injection needles,
syringes and implantable subcutaneous drug delivery devices;
infusion sets; lancets; lancing devices for delivering
medication; drug eluting stents; bio-absorbable stents;
stent grafts; medical diagnostic apparatus used to detect
and measure the level of substances in body fluids;
apparatus for measuring dosages and delivering
pharmaceuticals, namely, medical pumps and pens;
electromedical rehabilitative and pain management products
for clinical and home use, namely, electrical nerve and
muscle stimulators, ultrasonic stimulators, magnet therapy
stimulators and laser therapy stimulators;
electronic-kinetic transdermal drug delivery control unit
for the treatment of diseases.
Formulations comprising a levodopa amide derivative and a monovalent, divalent and/or trivalent acid, which are stable for at least 24 hours at room temperature are provided.
A61K 47/12 - Acides carboxyliquesLeurs sels ou anhydrides
A61K 47/18 - AminesAmidesUréesComposés d’ammonium quaternaireAcides aminésOligopeptides ayant jusqu’à cinq acides aminés
A61K 47/20 - Composés organiques, p. ex. hydrocarbures naturels ou synthétiques, polyoléfines, huile minérale, gelée de pétrole ou ozocérite contenant du soufre, p. ex. sulfoxyde de diméthyle [DMSO], docusate, laurylsulfate de sodium ou acides aminosulfoniques
05 - Produits pharmaceutiques, vétérinaires et hygièniques
10 - Appareils et instruments médicaux
Produits et services
(1) Pharmaceutical preparations for preventing and treating conditions, diseases, and disorders of the central nervous, neurological, cardiovascular, endocrine, gastric and gastroenteric, hematologic, immunologic, inflammatory, osteologic, and respiratory systems; pharmaceutical preparations for use in prevention and treatment of allergies and allergic responses, metabolic disorders and pharmaceutical preparations for the treatment of psychiatric diseases and disorders namely mood disorders, anxiety disorders, cognitive disorders, schizophrenia, and psychoses, infection and infectious diseases, pain; delivery kits comprising dressings for medical, surgical, and veterinary use.
(2) Medical apparatus, namely, infusion pumps for administering drugs; medical apparatus and medical instruments for administering fluid, drugs, arid nutrition, namely, infusion pumps, patch pumps, wearable injectors, and handheld injectors; drug delivery devices and accessories thereof, namely, catheters, pen needles, injection needles, syringes and implantable subcutaneous drug delivery devices; infusion pumps; jet injectors for medical purposes, medical tubing for administering drugs; medical apparatus, namely, implantable ports; medical apparatus, namely, infusion and injection devices for administering drugs; medical apparatus and medical instruments for administering fluid, drugs, and nutrition, namely, infusion pumps, patch pumps, wearable injectors, and handheld injectors; medical syringes; medical devices in the nature of infusion pumps for monitoring the infusion of drugs for use with integrated software for transmission and receiving of drug infusion data, data related to the infusion pumps, drug infusion monitoring, filling and emptying of the drug vials, and patient's behavior and reaction to drugs sold as a unit therewith; drug delivery devices and accessories thereof, namely, catheters, pen needles, injection needles, syringes and patches; lancets; diabetic lancing devices; drug-eluting stents; bio-absorbable stents; stent grafts; apparatus used in implementing diagnosis tests designed to detect medical and health parameters in patient, namely, vital signs; apparatus for measuring dosages and delivering pharmaceuticals, namely, medical pumps and pens; electromedical rehabilitative and pain management products for clinical and home use, namely, electrical nerve and muscle stimulators, ultrasonic stimulators, magnet therapy stimulators and laser therapy stimulators; electronic-kinetic transdermal drug delivery control unit for the treatment of diseases.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
10 - Appareils et instruments médicaux
Produits et services
Pharmaceuticals, namely, pharmaceutical preparations for use in preventing and treating conditions, diseases, or disorders of the central nervous, neurological, cardiovascular, endocrine, gastric or gastroenteric, hematologic, immunologic, inflammatory, osteologic, or respiratory systems; pharmaceutical preparations for use in prevention and treatment of allergies or allergic responses, metabolic disorders, psychiatric and emotional disorders, infection and infectious diseases, pain; drug delivery kits comprising dressings for medical, surgical, and veterinary use [ ; drug delivery agents, namely, transdermal patches sold with medication for use in the treatment of conditions, diseases or disorders of the central nervous, neurological, cardiovascular, endocrine, gastric or gastroenteric, hematologic, immunologic, inflammatory, osteologic, or respiratory systems ] Medical devices for delivery of medicated and pharmaceutical preparations, namely, implantable drug delivery pumps, drug delivery catheters, drug delivery patches sold without medication, subcutaneous drug delivery pumps, subcutaneous drug delivery patch pumps, refillable drug delivery pumps, and infusion drug delivery pumps; drug delivery device sold empty, namely, syringes, infusion drug delivery pumps; infusion sets; electromagnetic drug delivery apparatus for medical use; medical apparatus, namely, implantable ports; medical apparatus, namely, infusion and injection devices for administering drugs; medical apparatus and medical instruments for administering fluid, drugs, and nutrition, namely, infusion pumps, patch pumps being adherable subcutaneous drug delivery pumps, wearable medication injectors, wearable subcutaneous drug delivery pumps, and handheld medication injectors; medical syringes; medical devices in the nature of infusion pumps for drug infusion and for monitoring the infusion of drugs with integrated recorded software for transmission and receiving of drug infusion data, data related to the infusion pumps, drug infusion monitoring, filling and emptying of drug vials, and patient's behavior and reaction to drugs, sold as a unit therewith; drug delivery devices, namely, catheters, injection pen needles, injection needles, injection syringes and implantable subcutaneous drug delivery pumps; lancets; medical lancing devices for delivering medication, sold empty; drug eluting stents; bio-absorbable stents; synthetic stent grafts; medical diagnostic apparatus used to detect and measure the level of substances in body fluids; medical apparatus for measuring dosages and delivering pharmaceuticals, namely, infusion drug delivery pumps, subcutaneous drug delivery wearable pumps, subcutaneous drug delivery patch pumps, implantable drug delivery pumps and injection pens; electromedical rehabilitative and pain management products for clinical and home use, namely, electrical nerve and muscle stimulators, ultrasonic stimulators, magnet therapy stimulators and laser therapy stimulators; electronickinetic transdermal drug delivery control unit for the treatment of diseases
86.
Device for subcutaneous delivery of fluid medicament
An improved device delivers a fluid medicament to the subcutaneous tissue of a user. The device is better suited for patients with Parkinson's Disease and other central nervous system disorders, than conventional infusion devices. The device can include a reusable part including a drive component (e.g., motor) and control electronics and a disposable part including a medicament reservoir. Medicament can be evacuated from the medicament reservoir by a plunger assembly that includes a plunger attached to a lead screw that is rotated by a nut, all within the disposable part. The device can be fluidically coupled with the tissue via a flexible cannula. Various embodiments relate to an improved cannula insertion mechanism that delivers the cannula under a force applied by a spring. Various embodiments relate to improved filling of the device, for example, using a vial adapter and an automated filling station.
A61M 5/142 - Perfusion sous pression, p. ex. utilisant des pompes
A61M 5/145 - Perfusion sous pression, p. ex. utilisant des pompes utilisant des réservoirs sous pression, p. ex. au moyen de pistons
A61M 5/315 - PistonsTiges de pistonGuidage, blocage, ou limitation des mouvements de la tigeAccessoires disposés sur la tige pour faciliter le dosage
A61M 5/172 - Moyens pour commander l'écoulement des agents vers le corps ou pour doser les agents à introduire dans le corps, p. ex. compteurs de goutte-à-goutte électriques ou électroniques
Disclosed herein, in part, are processes making and purifying L-dopamide free base, such as purified pharmaceutically acceptable L-dopamide free base substantially free of L-dopa. Such processes are useful for providing L-dopamide for the treatment of neurodegenerative disorders such as Parkinson's disease.
A61K 31/165 - Amides, p. ex. acides hydroxamiques ayant des cycles aromatiques, p. ex. colchicine, aténolol, progabide
C07C 237/20 - Amides d'acides carboxyliques, le squelette carboné de la partie acide étant substitué de plus par des groupes amino ayant les atomes de carbone des groupes carboxamide liés à des atomes de carbone acycliques du squelette carboné le squelette carboné contenant des cycles aromatiques à six chaînons
Disclosed herein are formulations containing carbidopa and optionally levodopa, arginine, and other components that have reduced levels of impurities and toxins, particularly degradation productions. Also disclosed herein are methods of treatment diseases or conditions relating to a loss of dopamine or dopaminergic neurons using such formulations, methods of making such formulations, and kits that include such formulations.
A61K 47/22 - Composés hétérocycliques, p. ex. acide ascorbique, tocophérol ou pyrrolidones
A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 47/20 - Composés organiques, p. ex. hydrocarbures naturels ou synthétiques, polyoléfines, huile minérale, gelée de pétrole ou ozocérite contenant du soufre, p. ex. sulfoxyde de diméthyle [DMSO], docusate, laurylsulfate de sodium ou acides aminosulfoniques
A61K 31/133 - Amines, p. ex. amantadine ayant des groupes hydroxyle, p. ex. sphingosine
An improved device delivers a fluid medicament to the subcutaneous tissue of a user. The device is better suited for patients with Parkinson's Disease and other central nervous system disorders, than conventional infusion devices. The device can include a reusable part including a drive component (e.g., motor) and control electronics and a disposable part including a medicament reservoir. Medicament can be evacuated from the medicament reservoir by a plunger assembly that includes a plunger attached to a lead screw that is rotated by a nut, all within the disposable part. The device can be fluidically coupled with the tissue via a flexible cannula. Various embodiments relate to an improved cannula insertion mechanism that delivers the cannula under a force applied by a spring. Various embodiments relate to improved filling of the device, for example, using a vial adapter and an automated filling station.
A61M 5/142 - Perfusion sous pression, p. ex. utilisant des pompes
A61M 5/145 - Perfusion sous pression, p. ex. utilisant des pompes utilisant des réservoirs sous pression, p. ex. au moyen de pistons
A61M 5/315 - PistonsTiges de pistonGuidage, blocage, ou limitation des mouvements de la tigeAccessoires disposés sur la tige pour faciliter le dosage
A61M 5/172 - Moyens pour commander l'écoulement des agents vers le corps ou pour doser les agents à introduire dans le corps, p. ex. compteurs de goutte-à-goutte électriques ou électroniques
An improved device delivers a fluid medicament to the subcutaneous tissue of a user. The device is better suited for patients with Parkinson's Disease and other central nervous system disorders, than conventional infusion devices. The device can include a reusable part including a drive component (e.g., motor) and control electronics and a disposable part including a medicament reservoir. Medicament can be evacuated from the medicament reservoir by a plunger assembly that includes a plunger attached to a lead screw that is rotated by a nut, all within the disposable part. The device can be fluidically coupled with the tissue via a flexible cannula. Various embodiments relate to an improved cannula insertion mechanism that delivers the cannula under a force applied by a spring. Various embodiments relate to improved filling of the device, for example, using a vial adapter and an automated filling station.
A61M 5/142 - Perfusion sous pression, p. ex. utilisant des pompes
A61M 5/145 - Perfusion sous pression, p. ex. utilisant des pompes utilisant des réservoirs sous pression, p. ex. au moyen de pistons
A61M 5/315 - PistonsTiges de pistonGuidage, blocage, ou limitation des mouvements de la tigeAccessoires disposés sur la tige pour faciliter le dosage
A61M 5/172 - Moyens pour commander l'écoulement des agents vers le corps ou pour doser les agents à introduire dans le corps, p. ex. compteurs de goutte-à-goutte électriques ou électroniques
The application is directed to a vial adapter for attaching a medicament vial to a medicament delivery device having a reservoir adapted to receive and contain the medicament. The vial adapter can include a housing with two ports (one for attaching the reservoir and the other for attaching to the vial), a hollow needle that pierces septums sealing each of the reservoir and the vial, and a floating part that fixedly holds the hollow needle. Clearance between the floating part and the housing can enable relative movement of the floating part.
A61J 1/20 - Dispositions pour le transfert des liquides, p. ex. du flacon à la seringue
A61M 5/145 - Perfusion sous pression, p. ex. utilisant des pompes utilisant des réservoirs sous pression, p. ex. au moyen de pistons
A61M 5/142 - Perfusion sous pression, p. ex. utilisant des pompes
A61M 5/315 - PistonsTiges de pistonGuidage, blocage, ou limitation des mouvements de la tigeAccessoires disposés sur la tige pour faciliter le dosage
A61M 5/172 - Moyens pour commander l'écoulement des agents vers le corps ou pour doser les agents à introduire dans le corps, p. ex. compteurs de goutte-à-goutte électriques ou électroniques
Disclosed herein are formulations containing carbidopa and optionally levodopa, arginine, and other components that have reduced levels of impurities and toxins, particularly degradation productions. Also disclosed herein are methods of treatment diseases or conditions relating to a loss of dopamine or dopaminergic neurons using such formulations, methods of making such formulations, and kits that include such formulations.
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 31/133 - Amines, p. ex. amantadine ayant des groupes hydroxyle, p. ex. sphingosine
A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
A61K 47/18 - AminesAmidesUréesComposés d’ammonium quaternaireAcides aminésOligopeptides ayant jusqu’à cinq acides aminés
A61K 47/22 - Composés hétérocycliques, p. ex. acide ascorbique, tocophérol ou pyrrolidones
A61K 31/198 - Alpha-amino-acides, p. ex. alanine ou acide édétique [EDTA]
96.
CRYSTALLINE SALT FORMS OF LEVODOPA AMIDE AND METHODS OF MAKING AND USING SAME
The present disclosure discloses various salts of levodopa amide, and crystalline forms thereof, and pharmaceutical compositions comprising the salts or crystalline forms, which are useful in treatment of diseases or disorders characterized by neurodegeneration and/or reduced levels of brain dopamine such as Parkinson's disease.
C07C 237/20 - Amides d'acides carboxyliques, le squelette carboné de la partie acide étant substitué de plus par des groupes amino ayant les atomes de carbone des groupes carboxamide liés à des atomes de carbone acycliques du squelette carboné le squelette carboné contenant des cycles aromatiques à six chaînons
Disclosed herein, in part, are processes of large scale purification of a L- dopamide pharmaceutically acceptable salt and processes of making a purified pharmaceutically acceptable L-dopamide and pharmaceutically acceptable L-dopamide salts substantially free of L-dopa. Such processes are useful for providing L-dopamide for the treatment of neurodegenerative disorders such as Parkinson's disease.
C07C 237/20 - Amides d'acides carboxyliques, le squelette carboné de la partie acide étant substitué de plus par des groupes amino ayant les atomes de carbone des groupes carboxamide liés à des atomes de carbone acycliques du squelette carboné le squelette carboné contenant des cycles aromatiques à six chaînons
A crystalline levodopa amide free base and a process of making it are provided. Particularly, a substantially pure crystalline levodopa amide free base is disclosed, suitable for the preparation of pharmaceutical compositions for treatment of diseases or disorders characterized by neurodegeneration and/or reduced levels of brain dopamine such as Parkinson's disease.
C07C 237/20 - Amides d'acides carboxyliques, le squelette carboné de la partie acide étant substitué de plus par des groupes amino ayant les atomes de carbone des groupes carboxamide liés à des atomes de carbone acycliques du squelette carboné le squelette carboné contenant des cycles aromatiques à six chaînons
An improved device delivers a fluid medicament to the subcutaneous tissue of a user. The device is better suited for patients with Parkinson's Disease and other central nervous system disorders, than conventional infusion devices. The device can include a reusable part including a drive component (e.g., motor) and control electronics and a reusable part including a medicament reservoir. Medicament can be evacuated from the medicament reservoir by a plunger assembly that includes a plunger attached to a lead screw that is rotated by a nut, all within the disposable part. The device can be fluidically coupled with the tissue via a flexible cannula. Various embodiments relate to an improved cannula insertion mechanism that delivers the cannula under a force applied by a spring. Various embodiments relate to improved filling of the device, for example, using a vial adapter and an automated filling station.
Formulations containing a carbidopa prodrug and/or a levodopa prodrug, and one, two or more antioxidants are provided, having reduced levels of impurities and toxins, particularly oxidative degradation products such as hydrazine. These formulations are useful in treatment of diseases or conditions relating to a loss of dopamine or dopaminergic neurons, such as Parkinson's disease.
